Galapagos said it could not find a buyer for its cell therapy business and will wind down the unit, closing multiple global sites and eliminating roughly 365 positions. The company said nonbinding offers it received lacked the financing and terms required to sustain the business, prompting an orderly exit and redeployment of capital to other pipeline priorities. Management framed the move as a strategic reallocation of resources to areas with clearer commercial potential. The shutdown will generate one‑time closure costs and ongoing operating expenses during wind‑down, and Galapagos will continue to entertain acquisition proposals while the unit is shuttered.